SI1229922T1 - Zdravljenje raka z aplidinom - Google Patents

Zdravljenje raka z aplidinom

Info

Publication number
SI1229922T1
SI1229922T1 SI200030960T SI200030960T SI1229922T1 SI 1229922 T1 SI1229922 T1 SI 1229922T1 SI 200030960 T SI200030960 T SI 200030960T SI 200030960 T SI200030960 T SI 200030960T SI 1229922 T1 SI1229922 T1 SI 1229922T1
Authority
SI
Slovenia
Prior art keywords
aplidine
cancers
treatment
tumor
complementing
Prior art date
Application number
SI200030960T
Other languages
English (en)
Slovenian (sl)
Inventor
Glynn Thomas Pharma Faircloth
Chris University Of Gl Twelves
Luis Paz-Ares
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927006.8A external-priority patent/GB9927006D0/en
Priority claimed from GB0005701A external-priority patent/GB0005701D0/en
Priority claimed from GB0007639A external-priority patent/GB0007639D0/en
Priority claimed from GB0015496A external-priority patent/GB0015496D0/en
Priority claimed from GB0025209A external-priority patent/GB0025209D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of SI1229922T1 publication Critical patent/SI1229922T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200030960T 1999-11-15 2000-11-15 Zdravljenje raka z aplidinom SI1229922T1 (sl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9927006.8A GB9927006D0 (en) 1999-11-15 1999-11-15 Aplidine treatment of cancers
GB0005701A GB0005701D0 (en) 2000-03-09 2000-03-09 Antitumor utility of aplidine
GB0007639A GB0007639D0 (en) 2000-03-29 2000-03-29 Antitumour and anti-angiogenic compound
GB0015496A GB0015496D0 (en) 2000-06-23 2000-06-23 Antitumour and anti-angiogenic compound
GB0025209A GB0025209D0 (en) 2000-10-13 2000-10-13 Treatment of cancers
PCT/GB2000/004349 WO2001035974A2 (en) 1999-11-15 2000-11-15 Aplidine treatment of cancers
EP00976137A EP1229922B1 (en) 1999-11-15 2000-11-15 Aplidine treatment of cancers

Publications (1)

Publication Number Publication Date
SI1229922T1 true SI1229922T1 (sl) 2008-04-30

Family

ID=27515929

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030960T SI1229922T1 (sl) 1999-11-15 2000-11-15 Zdravljenje raka z aplidinom

Country Status (27)

Country Link
US (1) US20090298752A1 (https=)
EP (1) EP1229922B1 (https=)
JP (1) JP2003514025A (https=)
KR (1) KR100518986B1 (https=)
CN (1) CN1423564A (https=)
AT (1) ATE363910T1 (https=)
AU (1) AU780417B2 (https=)
BG (1) BG65381B1 (https=)
BR (1) BR0015811A (https=)
CA (1) CA2391502A1 (https=)
CY (1) CY1106825T1 (https=)
CZ (1) CZ302498B6 (https=)
DE (1) DE60035120T2 (https=)
DK (1) DK1229922T3 (https=)
ES (1) ES2288486T3 (https=)
HK (1) HK1045648B (https=)
HU (1) HUP0203906A2 (https=)
IL (1) IL149488A0 (https=)
MX (1) MXPA02004862A (https=)
NO (1) NO330719B1 (https=)
NZ (1) NZ518847A (https=)
PL (1) PL200922B1 (https=)
PT (1) PT1229922E (https=)
RU (1) RU2261104C2 (https=)
SI (1) SI1229922T1 (https=)
SK (1) SK287762B6 (https=)
WO (1) WO2001035974A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
IL155273A0 (en) 2000-10-12 2003-11-23 Pharma Mar Sa Pharmaceutical compositions comprising an aplidine compound
DE60229414D1 (de) * 2001-10-19 2008-11-27 Pharma Mar Sa Verwendung von aplidine in der behandlung von pankreaskrebs
PL368458A1 (en) * 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
EP1620117A4 (en) * 2003-03-12 2009-07-29 Pharma Mar Sa IMPROVED ANTITUMORAL TREATMENTS
AU2004218883B2 (en) 2003-03-12 2009-10-01 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
WO2007101235A2 (en) * 2006-02-28 2007-09-07 Pharma Mar, S.A. Improved antitumoral treatments
ATE479432T1 (de) * 2006-11-03 2010-09-15 Nerviano Medical Sciences Srl Verfahren zur verabreichung einer antitumoralen verbindung
RU2360712C1 (ru) * 2007-10-02 2009-07-10 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" Способ лечения местно-распространенного неоперабельного рака прямой кишки
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
CA2717409A1 (en) * 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved anticancer treatments
CN103463020B (zh) * 2013-09-23 2015-11-25 李淑兰 Lycojaponicumin A在制备治疗肾癌药物中的应用
KR102491180B1 (ko) 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342744A (en) * 1979-07-19 1982-08-03 Lever Brothers Company Hair treatment products
DE3161556D1 (en) * 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
DE3684868D1 (de) * 1985-09-20 1992-05-21 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5580871A (en) * 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
JPH09507233A (ja) * 1993-12-29 1997-07-22 マトリクス ファーマスーティカル，インコーポレイティド 細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
US6365597B1 (en) * 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
ES2151277T3 (es) * 1996-05-22 2000-12-16 Protarga Inc Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
US6030943A (en) * 1997-05-07 2000-02-29 Crumb; William J. Dehydrodidemnin B as an L-type calcium channel enhancer
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
CA2405779A1 (en) * 2000-04-07 2001-10-18 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
AU1305302A (en) * 2000-10-05 2002-04-15 Immunex Corp Nectin polypeptides, polynucleotides, methods of making and use thereof
IL155273A0 (en) * 2000-10-12 2003-11-23 Pharma Mar Sa Pharmaceutical compositions comprising an aplidine compound
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US6610399B1 (en) * 2000-11-17 2003-08-26 Structural Technologies, Llc Multi-layer, thermal protection and corrosion protection coating system for metallic tendons, especially for external post-tensioning systems
DE60229414D1 (de) * 2001-10-19 2008-11-27 Pharma Mar Sa Verwendung von aplidine in der behandlung von pankreaskrebs
EP1620117A4 (en) * 2003-03-12 2009-07-29 Pharma Mar Sa IMPROVED ANTITUMORAL TREATMENTS
AU2004218883B2 (en) * 2003-03-12 2009-10-01 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
JP2006523214A (ja) * 2003-03-21 2006-10-12 ジユーリー，マデレーン・エム タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007101235A2 (en) * 2006-02-28 2007-09-07 Pharma Mar, S.A. Improved antitumoral treatments
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments

Also Published As

Publication number Publication date
BG65381B1 (bg) 2008-05-30
PL355335A1 (en) 2004-04-19
HK1045648A1 (en) 2002-12-06
CZ302498B6 (cs) 2011-06-15
KR20020064313A (ko) 2002-08-07
CN1423564A (zh) 2003-06-11
MXPA02004862A (es) 2003-01-28
US20090298752A1 (en) 2009-12-03
WO2001035974A3 (en) 2001-11-01
CZ20021697A3 (cs) 2003-02-12
SK6592002A3 (en) 2003-08-05
AU1402301A (en) 2001-05-30
BG106714A (en) 2003-02-28
PL200922B1 (pl) 2009-02-27
DE60035120D1 (de) 2007-07-19
ATE363910T1 (de) 2007-06-15
CY1106825T1 (el) 2012-05-23
BR0015811A (pt) 2002-08-06
EP1229922B1 (en) 2007-06-06
RU2261104C2 (ru) 2005-09-27
DE60035120T2 (de) 2008-01-31
HK1045648B (en) 2007-09-21
ES2288486T3 (es) 2008-01-16
NZ518847A (en) 2004-02-27
RU2002115864A (ru) 2004-01-20
HUP0203906A2 (en) 2003-03-28
DK1229922T3 (da) 2007-10-08
NO20022293D0 (no) 2002-05-14
NO20022293L (no) 2002-07-05
SK287762B6 (sk) 2011-09-05
PT1229922E (pt) 2007-09-12
NO330719B1 (no) 2011-06-20
WO2001035974A2 (en) 2001-05-25
IL149488A0 (en) 2002-11-10
KR100518986B1 (ko) 2005-10-06
EP1229922A2 (en) 2002-08-14
CA2391502A1 (en) 2001-05-25
AU780417B2 (en) 2005-03-17
JP2003514025A (ja) 2003-04-15

Similar Documents

Publication Publication Date Title
PL355335A1 (en) Aplidine treatment of cancers
PL354540A1 (en) Drugs for the treatment of malignant tumours
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
JP2022088662A5 (https=)
NZ515975A (en) Anti-ErbB antibody-maytansinoid conjugates useful in the treatment of tumors characterised by the overexpression of an ErbB receptor
IL138330A0 (en) Polynucleotides, polypeptides and pharmaceutical compositions for treating lung cancer
HUP0203238A3 (en) Drugs for the treatment of malignant tumours, process for their preparation and pharmaceutical compositions containing them
WO1999038973A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
IL159859A (en) Antineoplastic combinations
AU5047800A (en) Breast, gastric and prostate cancer associated antigens and uses therefor
YU69903A (sh) Postupak i dozni oblik za lečenje tumora primenom tegafura, uracila, folne kiseline, paklitaksela i karboplatina
ZA200202822B (en) Oncolytic combinations for the treatment of cancer.
WO2000061756A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
CY1106525T1 (el) ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ hCG ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΟΥ ΜΕΤΑΣΤΑΤΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΜΑΣΤΟΥ
AU5302599A (en) Method for diagnosing bone metastasis of malignant tumor
BG108932A (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
ZA200106725B (en) Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral antiparasitic or antitumoral cytotoxic response.
IL160382A0 (en) Use of 4-pyridylmethylphthalazines for cancer treatment
ATE332139T1 (de) 1,2,4-benzotriazin-oxide enthaltende zubereitungen
SG148035A1 (en) Gene products differentially expressed in cancerous breast cells and their methods of use
AU1991901A (en) Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof
YU29803A (sh) Kombinacija kamptotekina i derivata stilbena za lečenje raka
WO2002081640A3 (en) Gene shinc-1 and diagnostic and therapeutic uses thereof
WO2000030587A3 (fr) INHIBITEURS DE L'ACTIVATION DE NF-λB, ET LEURS UTILISATIONS PHARMACEUTIQUES
UA30391A (uk) Спосіб лікування колоректального раку